{"id":"W2995532498","doi":"10.1093/neuonc/noz232","title":"A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE)","year":2019,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre; Ottawa Hospital; London Health Sciences Centre","funders":"National Cancer Institute; Deciphera Pharmaceuticals; Five Prime Therapeutics; American Society of Clinical Oncology; Sanofi; Celldex Therapeutics; AstraZeneca; Eli Lilly and Company","keywords":"Bevacizumab; Medicine; Concomitant; Clinical endpoint; Combination therapy; Internal medicine; Phases of clinical research; Hazard ratio; Adverse effect; Oncology; Randomized controlled trial; Progression-free survival; Surgery; Overall survival; Clinical trial; Chemotherapy; Confidence interval","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002898361,0.001889047,0.003131538,0.0005231472,0.0003969911,0.00110484,0.0009546899,0.001669469,0.005896279],"category_scores_gemma":[0.002406768,0.0007664312,0.001859388,0.0005411168,0.001385306,0.0009443378,0.0004904383,0.003011524,0.001048974],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009449828,"about_ca_system_score_gemma":0.001940258,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009247749,"about_ca_topic_score_gemma":0.002446104,"domain_scores_codex":[0.9989365,0.00062746,0.00006069594,0.0001634609,0.00007102757,0.0001408431],"domain_scores_gemma":[0.9983947,0.0003771822,0.0004123048,0.0001477089,0.0001198539,0.0005483011],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9765785,0.01074355,0.0006248367,0.0002742005,0.0006336482,0.00003268056,0.00003883941,0.0001962613,0.002275782,0.00006699205,0.0005808944,0.007953849],"study_design_scores_gemma":[0.9095393,0.08862255,0.000800845,0.00001313288,0.000242928,0.00002103601,0.0000120367,0.0001903123,0.0001853516,0.00006657955,0.0002980558,0.000007919062],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9835686,0.002743028,0.0008878604,0.0007767163,0.0008233699,0.008309697,0.001059749,0.0001198988,0.001710993],"genre_scores_gemma":[0.980162,0.002118463,0.002269541,0.001680407,0.0006407142,0.009131841,0.001533889,0.00003860911,0.002424623],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005896279,"threshold_uncertainty_score":0.01972497,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008743713209318665,"score_gpt":0.280442104597949,"score_spread":0.2716983913886303,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}